A weight-loss drug quietly lowered a marker of asthma inflammation. In 371 adults started on semaglutide ↗, the peptide sold as Ozempic and Wegovy, blood eosinophil counts fell by roughly a third, and they fell most in the patients who were not obese.
Eosinophils are a type of white blood cell. In people with allergic asthma they collect in the airways and drive the inflammation behind wheezing and attacks; the higher the blood count, the worse that "type 2" inflammation tends to run. The cell is recruited by interleukin-5, a signaling protein, and lung specialists already prescribe expensive antibody drugs that block that pathway, such as mepolizumab and benralizumab, for the specific job of dragging eosinophils down. So a common diabetes and obesity injection doing the same thing on its own is worth a look.
The study, published July 4 in BMC Pulmonary Medicine ↗, was a retrospective chart review at a single Shanghai clinic. The authors pulled blood counts before and after treatment for every patient first prescribed semaglutide in their outpatient department. Median eosinophil count dropped from 160 cells per microliter of blood to 110 (P less than 0.001), and the share of eosinophils among white cells fell from 2.2 percent to 1.6 percent. The proportion of patients sitting below 150 cells per microliter, a common threshold for low airway inflammation, rose from 44 percent to 66 percent.
The reduction showed up whether or not patients started inflamed. Both the group above 150 cells and the group already below it came down. That matters, because it argues against the simplest explanation, that the drug only helps people who were highly inflamed to begin with.
The subgroup split is the more interesting number. Patients with a body mass index under 28 lost more of their eosinophils than heavier patients did, 31.6 percent versus 21.0 percent (P = 0.037). If the effect were purely a byproduct of shedding fat, you would expect the opposite: the people with more weight to lose should show the bigger anti-inflammatory swing. They did not. And when the authors ran a regression to find what predicted the drop, body weight and lipid changes washed out. The only independent predictor left standing was how high the eosinophil count started.
That points, cautiously, at a direct effect. Semaglutide works through the GLP-1 receptor ↗, which sits not only on pancreas and brain cells but on immune cells, including eosinophils and the type 2 helper T cells that release interleukin-5. A growing set of experiments has GLP-1 signaling damping that type 2 inflammation in mouse and human airways. The blood-count drop here fits that picture better than it fits "they just lost weight."
What the study cannot say is whether any of this helps an actual asthmatic breathe. It measured a blood marker, not asthma attacks, lung function, or inhaler use. It had no placebo arm; it compared each patient to their own earlier bloodwork, which cannot separate the drug from regression to the mean or seasonal swings in allergy. It was one clinic, retrospective, and registered only after the fact (ChiCTR2500110394). The eosinophil signal is real and it is consistent across subgroups, but it is a hypothesis about asthma, not an answer.
That hypothesis is already being tested directly. Semaglutide is in prospective asthma trials in people with obesity, where the endpoint is whether the drug cuts attacks, not just cell counts. A real-world dataset like this one cannot settle that. What it adds is a reason to expect those airway trials might read out positive, and a hint that the mechanism runs deeper than the scale.